Vir Biotechnology (VIR) Preferred Stock Liabilities (2018 - 2019)

Vir Biotechnology has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $636.6 million for Q3 2019.

• Preferred Stock Liabilities for Q3 2019 came in at $636.6 million, up 105.93% year-over-year; the trailing twelve-month figure through Sep 2019 was $636.6 million (up 105.93% YoY), and the FY2018 annual result was $309.1 million, up 5.68% from the prior year.
• Preferred Stock Liabilities came in at $636.6 million for Q3 2019 at Vir Biotechnology, roughly flat from $636.6 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $636.6 million in Q2 2019 to a low of $307.2 million in Q2 2018.